KNSA - Company ID 0001730430
The table below shows Kiniksa Pharmaceuticals, Ltd.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $165.60M | $183.58M | $107.95M | $122.72M | $122.47M | $114.04M |
| Short-term investments | $248.48M | $60.05M | $98.42M | $67.89M | $59.73M | $209.44M |
| Receivables | $15.59M | $41.72M | $21.27M | $12.66M | $3.98M | - |
| Inventory | $54.90M | $26.36M | $31.12M | $21.60M | $3.67M | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $527.18M |
| $331.80M |
| $276.30M |
| $243.06M |
| $196.45M |
| $333.25M |
| Property, plant & equipment | $1.94M | $662.00K | $734.00K | $1.66M | $2.83M | $4.05M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $763.63M | $580.55M | $526.32M | $459.67M | $232.80M | $349.46M |
| Accounts payable | $2.03M | $2.04M | $8.25M | $7.90M | $1.87M | $503.00K |
| Total current liabilities | $139.18M | $100.62M | $63.67M | $47.07M | $44.82M | $31.85M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $196.03M | $142.12M | $87.48M | $63.52M | $47.76M | $37.53M |
| Retained earnings | -$462.14M | -$521.14M | -$477.95M | -$492.03M | -$675.40M | -$517.47M |
| Total equity | $567.61M | $438.44M | $438.84M | $396.15M | $185.04M | $311.94M |